Please use this identifier to cite or link to this item: https://doi.org/10.1002/adtp.202100091
DC FieldValue
dc.titleHarnessing CURATE.AI for N-of-1 Optimization Analysis of Combination Therapy in Hypertension Patients: A Retrospective Case Series
dc.contributor.authorTruong, ATL
dc.contributor.authorTan, LWJ
dc.contributor.authorChew, KA
dc.contributor.authorVillaraza, S
dc.contributor.authorSiongco, P
dc.contributor.authorBlasiak, A
dc.contributor.authorChen, C
dc.contributor.authorHo, D
dc.date.accessioned2021-11-02T03:03:42Z
dc.date.available2021-11-02T03:03:42Z
dc.date.issued2021-10-01
dc.identifier.citationTruong, ATL, Tan, LWJ, Chew, KA, Villaraza, S, Siongco, P, Blasiak, A, Chen, C, Ho, D (2021-10-01). Harnessing CURATE.AI for N-of-1 Optimization Analysis of Combination Therapy in Hypertension Patients: A Retrospective Case Series. Advanced Therapeutics 4 (10) : 2100091-2100091. ScholarBank@NUS Repository. https://doi.org/10.1002/adtp.202100091
dc.identifier.issn23663987
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/205355
dc.description.abstractHypertension is a global public health challenge that imposes a significant burden on patients and healthcare systems. Conventional treatment involves dose escalation of an antihypertensive drug, and if the desired response is not achieved, patients are prescribed another drug, often in combination with other therapies. Importantly, drug synergy is dose-, time- and patient-dependent. Coupled with the challenges of intra- and inter-individual variability, standard care can lead to sub-optimal outcomes, additional visits, and adherence issues. Furthermore, these factors can cause the additional complication of patients being misperceived as refractory to regimens that are sub-optimally administered. A scalable strategy that can longitudinally optimize patient response would be a powerful advance for chronic disease management. This four-patient case series reports the application of CURATE.AI as a mechanism-independent and disease-agnostic platform for a retrospective N-of-1 (personalized) dose optimization using each patient's own data, including drug doses and corresponding changes in blood pressures. This approach may enable the rapid prediction of treatment response and the identification of optimal doses that may yield improved outcomes. CURATE.AI can be implemented in clinical workflows without creating additional burden of extensive data collection. The findings from this study support the prospective validation of CURATE.AI to optimize hypertension management.
dc.publisherWiley
dc.sourceElements
dc.typeArticle
dc.date.updated2021-11-01T04:16:16Z
dc.contributor.departmentLIFE SCIENCES INSTITUTE
dc.description.doi10.1002/adtp.202100091
dc.description.sourcetitleAdvanced Therapeutics
dc.description.volume4
dc.description.issue10
dc.description.page2100091-2100091
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Harnessing CURATE.AI for N-of-1 Optimization Analysisof Combination Therapy in Hypertension Patients - A Retrospective Case Series.pdfPublished version960.84 kBAdobe PDF

CLOSED

None

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.